article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells). NK cells can be readily extracted from umbilical cord blood or peripheral blood of adult donors.

Therapies 118
article thumbnail

Applications of engineered exosomes in drugging noncoding RNAs for cancer therapy

Chemical Biology and Drug Design

Abstract Noncoding RNAs (ncRNAs) are engaged in key cell biological and pathological events, and their expression alteration is connected to cancer progression both directly and indirectly. However, there are several limitations, including delivery, uptake, and short half-life, in the application of ncRNAs in cancer treatment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

University of Edinburgh spinout Cellinta will develop gene therapies for cancer

The Pharma Data

. A biotech company spun out of the University of Edinburgh will utilise research to develop new gene therapies to target different types of cancer. The funding will be used to develop a pipeline of ‘highly selective’ gene therapies targeting cancer stem cells in a variety of solid tumour types.

article thumbnail

#ScienceSaturday: March 2, 2024

KIF1A

Read the Article Rare Roundup The Jackson Laboratory offers “Exploring Rare Disease Through Translational Research” MiniCourse Human health is incredibly complex; developing safe, effective treatments requires knowledge of molecular mechanisms, cell biology, and drug administration.

article thumbnail

Patient-derived organoids in disease modelling

Drug Target Review

This is particularly pertinent in immune-based cell therapies like CAR-T, where animals do not mimic the human immune response. The full potential of PDOs would be to shorten the time and costs associated with medicine creation, and then use PDO therapies to treat patients effectively.

Disease 122
article thumbnail

Building better brain models for Parkinson’s disease and beyond

Drug Target Review

Turning this tide, Professor Jens Christian Schwamborn, a cell biology expert at the University of Luxembourg and co-founder of OrganoTherapeutics , is leading a groundbreaking effort to transform our understanding and treatment of these debilitating diseases.

Disease 52
article thumbnail

A T cell receptor immunotherapy against a novel target

Drug Target Review

How does Immunocore’s TCR technology differentiate itself from other approaches to targeted cancer therapy? Can you explain the mechanism of action by which ImmTAC molecules selectively target and kill cancer cells?